Related references
Note: Only part of the references are listed.Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor
Tae Nakano-Tateno et al.
ENDOCRINE PATHOLOGY (2021)
Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Bastiaan Sol et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab
Mario Caccese et al.
ANTI-CANCER DRUGS (2020)
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy
Majid Assadi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey
Ulf Elbelt et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
Shinsuke Uraki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness
Zihao Wang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature
Camille Duhamel et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
Zachary K. Christian et al.
INTERDISCIPLINARY NEUROSURGERY-ADVANCED TECHNIQUES AND CASE MANAGEMENT (2020)
An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors
Omalkhaire M. Alshaikh et al.
ENDOCRINE PATHOLOGY (2019)
Immune checkpoint inhibitors
Enfu Hui
JOURNAL OF CELL BIOLOGY (2019)
Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease
Isabel Weigand et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma
Lauren E. Rotman et al.
WORLD NEUROSURGERY (2019)
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
G. Giuffrida et al.
ENDOCRINE CONNECTIONS (2019)
Cushing's disease due to somatic USP8 mutations: a systematic review and meta-analysis
Ingrid Quevedo Wanichi et al.
PITUITARY (2019)
Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Annamaria Colao et al.
ENDOKRYNOLOGIA POLSKA (2019)
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial
Rafael L. Batista et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
Dongyun Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Solomon Tadesse et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Management of Dopamine Agonist-Resistant Prolactinoma
Dominique Maiter
NEUROENDOCRINOLOGY (2019)
Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review
Yong Wang et al.
WORLD NEUROSURGERY (2019)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Gerald Raverot et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
A. Ciresi et al.
BMC ENDOCRINE DISORDERS (2018)
Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study
Xiaohai Liu et al.
WORLD NEUROSURGERY (2018)
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved issues, and Future Directions
Luis V. Syro et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab
Andrew L. Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Thyroid disorders induced by checkpoint inhibitors
Silvia Martina Ferrari et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR
Ernesto Sosa-Eroza et al.
ENDOCRINE (2018)
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting
Claudia Pivonello et al.
ENDOCRINE (2018)
How effective is temozolomide for treating pituitary tumours and when should it be used?
Carmel Halevy et al.
PITUITARY (2017)
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Rudolf A. Werner et al.
ONCOTARGET (2017)
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
Helene Lasolle et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
Waseem Touma et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2017)
Intra-individual variability in TSH levels of healthy women during the first half of pregnancy
Mayte Murillo-Llorente et al.
Endocrinologia Diabetes y Nutricion (2017)
Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease
Amy S. Joehlin-Price et al.
DIAGNOSTIC PATHOLOGY (2017)
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas
M. Victoria Recouvreux et al.
JOURNAL OF ENDOCRINOLOGY (2016)
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
Marco Losa et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment
Mariana Campdera et al.
PITUITARY (2016)
Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes
Shahrzad Jalali et al.
ENDOCRINOLOGY (2016)
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists
Y. Greenman et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report
Joanna Waligorska-Stachura et al.
JOURNAL OF NEUROSURGERY (2016)
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Marie Chanal et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study
Lucio Vilar et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2016)
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Yu Mei et al.
ONCOTARGET (2016)
Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports
Yan Ji et al.
NEURO-ONCOLOGY PRACTICE (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Recurrent gain-of-function USP8 mutations in Cushing's disease
Zeng-Yi Ma et al.
CELL RESEARCH (2015)
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Misu Lee et al.
CLINICAL CANCER RESEARCH (2015)
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy
Leonardo Vieira Neto et al.
CLINICAL ENDOCRINOLOGY (2015)
The Use of Ga-68 DOTATATE PET/CT for Diagnostic Assessment and Monitoring of Lu-177 DOTATATE Therapy in Pituitary Carcinoma
Fuad Novruzov et al.
CLINICAL NUCLEAR MEDICINE (2015)
ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice
Xiaohai Liu et al.
ENDOCRINOLOGY (2015)
Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
Daniel Bengtsson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease
Ning-Ai Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center
Filippo Ceccato et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy
Constantin Lapa et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
Oscar D. Bruno et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
Erika Peverelli et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
Mutations in the deubiquitinase gene USP8 cause Cushing's disease
Martin Reincke et al.
NATURE GENETICS (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
Eric Monsalves et al.
ENDOCRINE-RELATED CANCER (2014)
Activation of the Dopamine Receptor Type-2 (DRD2) Promoter by 9-Cis Retinoic Acid in a Cellular Model of Cushing's Disease Mediates the Inhibition of Cell Proliferation and ACTH Secretion Without a Complete Corticotroph-to-Melanotroph Transdifferentiation
Gianluca Occhi et al.
ENDOCRINOLOGY (2014)
Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM): A Case Series
Brad E. Zacharia et al.
NEUROSURGERY (2014)
Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
Jan Komor et al.
PITUITARY (2014)
Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation
Jillian Maclean et al.
PITUITARY (2014)
Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?
M. Barbot et al.
PITUITARY (2014)
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
Odelia Cooper et al.
ENDOCRINE (2014)
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
Robert L. Fine et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature
Kentaro Suda et al.
ENDOCRINE JOURNAL (2013)
mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features
Emir Ahmed Sajjad et al.
ENDOCRINE PATHOLOGY (2013)
ACTH-secreting Crooke cell carcinoma of the pituitary
Gabor L. Kovacs et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
Toshio Hirohata et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
Antonio Bianchi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas
Erica C. Garcia et al.
PITUITARY (2013)
Temozolomide in the management of dopamine agonist-resistant prolactinomas
B. C. Whitelaw et al.
CLINICAL ENDOCRINOLOGY (2012)
Potential Role for Retinoic Acid in Patients with Cushing's Disease
Francesca Pecori Giraldi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Lapatinib for Advanced or Metastatic Breast Cancer
Frans L. Opdam et al.
ONCOLOGIST (2012)
New targeted therapies in pituitary carcinoma resistant to temozolomide
Emmanuel Jouanneau et al.
PITUITARY (2012)
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature
A. K. Annamalai et al.
PITUITARY (2012)
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment
S. Baldari et al.
Pituitary (2012)
Diagnosis of Men-I Syndrome on 68Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE
Santosh Kumar Gupta et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2012)
Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
Ann I. McCormack et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2011)
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
Aart-Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Hidenori Fukuoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Anna Imhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy
Hidenori Fukuoka et al.
MOLECULAR ENDOCRINOLOGY (2011)
Medical treatment of prolactinomas
Annamaria Colao et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor
Marie S. Thearle et al.
PITUITARY (2011)
Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma
Alessandra Fusco et al.
PITUITARY (2011)
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR
Lucio Vilar et al.
PITUITARY (2011)
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
Ning-Ai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases
Marco Losa et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases
H. Bode et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2010)
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas
Maria Chiara Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
Zachary M. Bush et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
Gerald Raverot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly
Priscilla Mattar et al.
NEUROENDOCRINOLOGY (2010)
Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
Richard A. Feelders et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease
Lucio Vilar et al.
PITUITARY (2010)
MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
Stephen Yip et al.
CLINICAL CANCER RESEARCH (2009)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
Ann I. McCormack et al.
CLINICAL ENDOCRINOLOGY (2009)
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
Peter J. Trainer et al.
CLINICAL ENDOCRINOLOGY (2009)
Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
Alexander Gorshtein et al.
ENDOCRINE-RELATED CANCER (2009)
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
C. Hagen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide
Raquel S. Jallad et al.
NEUROENDOCRINOLOGY (2009)
Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas
Marta Labeur et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2009)
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands
George Vlotides et al.
CANCER RESEARCH (2008)
Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells
Sara Bondioni et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
Masami Ono et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review
Umberto Goglia et al.
PITUITARY (2008)
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
Kalman Kovacs et al.
ACTA NEUROPATHOLOGICA (2008)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm
Luis V. Syro et al.
CLINICAL ENDOCRINOLOGY (2006)
Long-term response of pituitary carcinoma to temozolomide - Report of two cases
Camilo E. Fadul et al.
JOURNAL OF NEUROSURGERY (2006)
Retinoic acid as a novel medical therapy for Cushing's disease in dogs
Victor Castillo et al.
ENDOCRINOLOGY (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Targeted modulation of MGMT: Clinical implications
LL Liu et al.
CLINICAL CANCER RESEARCH (2006)
Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients
B Gatta et al.
CLINICAL ENDOCRINOLOGY (2005)
Enhanced protein kinase B/Akt signalling in pituitary tumours
M Musat et al.
ENDOCRINE-RELATED CANCER (2005)
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
D Selvarajah et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
R Cozzi et al.
CLINICAL ENDOCRINOLOGY (2004)
Retinoic acid prevents experimental Cushing syndrome
M Páez-Pereda et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: A possible mechanism for the inhibition of apoptosis by retinoic acid
HJ Kang et al.
EXPERIMENTAL CELL RESEARCH (2000)
Share Paper
